- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06123338
식도위암 환자를 대상으로 Trastuzumab 및 화학요법을 병용한 Pembrolizumab에 대한 연구
절제 가능한 HER2+ 식도위 종양에서 Trastuzumab 및 화학요법을 병용한 신보강 Pembrolizumab의 단일군, 다기관 제2상 연구
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
연구 개요
상태
상세 설명
Eligible patients will receive 8 peri-operative cycles of pembrolizumab and trastuzumab with chemotherapy (fluoropyrimidine/oxaliplatin doublet for patients initially enrolled and subsequently FLOT [5-fluorouracil, oxaliplatin and docetaxel] followed by pembrolizumab and trastuzumab maintenance to complete 1 total year of therapy.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Yelena Janjigian, MD
- 전화번호: 646-888-4186
- 이메일: janjigiy@mskcc.org
연구 연락처 백업
- 이름: Samuel Cytryn, MD
- 이메일: cytryns@mskcc.org
연구 장소
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- 모병
- Massachusetts General Hospital (Data Collection Only)
-
연락하다:
- Samuel Klempner, MD
- 전화번호: 617-724-4000
-
-
New Jersey
-
Basking Ridge, New Jersey, 미국, 07920
- 모병
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
-
연락하다:
- Yelena Janjigian, MD
- 전화번호: 646-888-4186
-
Middletown, New Jersey, 미국, 07748
- 모병
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
연락하다:
- Yelena Janjigian, MD
- 전화번호: 646-888-4186
-
Montvale, New Jersey, 미국, 07645
- 모병
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
연락하다:
- Yelena Janjigian, MD
- 전화번호: 646-888-4186
-
-
New York
-
Commack, New York, 미국, 11725
- 모병
- Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity)
-
연락하다:
- Yelena Janjigian, MD
- 전화번호: 646-888-4186
-
Harrison, New York, 미국, 10604
- 모병
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)
-
연락하다:
- Yelena Janjigian, MD
- 전화번호: 646-888-4186
-
New York, New York, 미국, 10065
- 모병
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
연락하다:
- Yelena Y Janjigian, MD
- 전화번호: 646-888-4186
-
Uniondale, New York, 미국, 11553
- 모병
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)
-
연락하다:
- Yelena Janjigian, MD
- 전화번호: 646-888-4186
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 모집하지 않고 적극적으로
- University of Pennsylvania (Data Collection Only)
-
-
Texas
-
Houston, Texas, 미국, 77030
- 모병
- MD Anderson Cancer Center (Data Collection Only)
-
연락하다:
- Jennifer Li, MD
- 전화번호: 855-760-5921
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age 18 years or older at time of signing informed consent.
- ECOG performance status 0-1.
- HER2+ esophageal, GEJ, or gastric adenocarcinoma biopsy or resection specimen as defined by local HER2 IHC3+ or IHC 2+/FISH>2.0 expression.
- Complete surgical resection of the primary tumor must be achievable
- Demonstrate adequate organ function as defined in Table 1.
Table 1 - Organ Function Requirements for Eligibility Hematological
-
Absolute neutrophil count (ANC): ≥1,500 /mcL
-
Platelets: ≥100,000 / mcL
-
Hemoglobin: ≥8 g/dL Renal
-
Creatinine clearance: ≥ 50 mL/minute Hepatic
-
Serum total bilirubin: ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN. Except patients with Gilbert's disease (≤3x ULN)
-
AST and ALT: ≤ 2.5 X ULN
-
Albumin: >3 mg/dL Coagulation
-
International normalized ratio (INR) OR prothrombin time (PT) Activated partial thromboplastin time (aPTT): <1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants
-
Male participants: A male participant must agree to use contraception as detailed in Section 15.3 of this protocol during the treatment period and for at least 230 days (5 terminal half-lives of trastuzumab [140] plus an additional 90 days [spermatogenesis cycle]) after the last dose of study treatment and refrain from donating sperm during this period.
-
Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
- Not a woman of childbearing potential (WOCBP) as defined in section 15.3 OR
- A WOCBP who agrees to follow the contraceptive guidance in section 15.3 during the treatment period and for at least 170 days (140 days plus an additional 30 days [menstruation cycle]) after the last dose of study treatment.
Exclusion Criteria:
-
Presence of metastatic or recurrent disease.
-
Has received prior treatment for esophagogastric cancer
-
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 agent.
-
Has received prior therapy with an anti-HER2 agent
-
Left ventricular ejection fraction <50% within 1 month of screening by MUGA or echocardiogram. Patients with an ejection fraction 45-49% may be permissible in the absence of any cardiac symptoms, if cleared by a cardiologist, and per the investigator's discresion.
-
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
-
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
-
Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., dexamethasone containing antiemetic regimen or steroids as CT scan contrast premedication) may be enrolled.
-
The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
-
Has a known history of active TB (Bacillus tuberculosis)
-
Hypersensitivity to pembrolizumab or any of its excipients
-
Has been diagnosed or treated for another malignancy in the past 3 years (not including non-melanoma skin cancer)
-
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
-
Has known history of, or any evidence of active, non-infectious pneumonitis.
-
Has an active infection requiring systemic therapy.
-
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
-
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
-
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
-
A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
-
Has had an allogeneic tissue or solid organ transplant
-
Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease; systemic lupus erythematosus; Wegener syndrome [granulomatosis with polyangiitis]; myasthenia gravis; Graves' disease; rheumatoid arthritis, hypophysitis, uveitis) within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:
- Subjects with vitiligo or alopecia
- Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment.
- Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
-
Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
-
Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
-
Is unwilling to give written informed consent, unwilling to participate, or unable to comply with the protocol for the duration of the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Esophagogastric Cancer
Participants will have a diagnosis of resectable HER2+ (IHC 3+ or IHC 2+/FISH ratio >2.0) esophageal, GEJ or gastric cancer. |
Pembrolizumab will be administered on an every 3-week dosing schedule Trastuzumab will be administered on an every 3-week dosing schedule Oxaliplatin every 3 weeks, +/-7 days Capecitabine twice daily on days 1 to 14 every 3 weeks or 5-FU on days 1 to 5 every 3 weeks 5-Fluorouracil administered as a 24 hour IV continuous infusion once every 2 weeks Docetaxel administered intravenously once every 2 weeks. will be collected (optionally) will be collected (optionally) |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Event-free survival (EFS)
기간: 2 years
|
EFS is defined as the time from start of treatment to time of disease progression, recurrence, or death, whichever occurs first. |
2 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 부위별 신생물
- 신생물
- 위장관 신생물
- 소화계 신생물
- 소화기계 질환
- 위장병
- 두경부 신생물
- 식도 질환
- 식도 신생물
- 아미노산, 펩티드 및 단백질
- 단백질
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 핵산, 뉴클레오티드 및 뉴 클레오 시드
- 탄화수소
- 사이클로 파라핀
- 탄화수소, alicyclic
- 탄화수소, 순환
- 테르펜
- 항체, 모노클로 날, 인간화
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 조정 복합체
- 박습니다
- 사이클로 데카네
- Diterpenes
- 데 옥시 시티 딘
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- 뉴 클레오 시드
- 우라실
- 피리 미디 논
- 데 옥시 리보 뉴 클레오 시드
- 소화 시스템 생리적 현상
- 소화 시스템 및 경구 생리적 현상
- 도세탁셀
- 트라스투주맙
- 카페시타빈
- 옥살리플라틴
- 플루오로우라실
- 펨브 롤리 주맙
- 깨끗하게 함
기타 연구 ID 번호
- 23-124
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .